Challenges in severe asthma: Do we need new drugs or new biomarkers?
Severe asthma is a complex, heterogenous airway condition. There have been significant advances in severe asthma management in the past decade using monoclonal antibody therapies that target the inflammatory component of the disease. Patient selection has been paramount for the success of these biol...
Main Authors: | Adil Adatia, Harissios Vliagoftis |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.921967/full |
Similar Items
-
Protease-activated receptor-2: Role in asthma pathogenesis and utility as a biomarker of disease severity
by: Vivek Dipak Gandhi, et al.
Published: (2022-07-01) -
Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice
by: Konstantinos Porpodis, et al.
Published: (2022-06-01) -
Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
by: Agamemnon Bakakos, et al.
Published: (2021-04-01) -
Editorial: Road trip from mild to severe asthmatic inflammation: the traffic lights of biomarkers in asthma management
by: Konstantinos Porpodis, et al.
Published: (2023-11-01) -
Severe eosinophilic bronchial asthma: new therapeutic options
by: N. M. Nenasheva
Published: (2018-10-01)